DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

1380 Lewis K. Riddle of biofilm resistance. Antimicrob Agents
Chemother, 2001, 45:999–1007.
Lim D, Strynadka NC. Structural basis for the beta lactam resistance
of PBP2a from methicillin-resistant Staphylococcus
aureus. Nat Struct Biol, 2002, 9:870–876.
Louie A, Kaw P, Liu W, et al. Pharmacodynamics of daptomycin
in a murine thigh model of Staphylococcus aureus infection.
Antimicrob Agents Chemother, 2001, 45:845–851.
Mahillon J, Chandler M. Insertion sequences. Microbiol Mol
Biol Rev, 1998, 62:725–774.
Marr KA, Lyons CN, Ha K, et al. Inducible azole resistance
associated with a heterogeneous phenotype in Candida albicans.
Antimicrob Agents Chemother, 2001, 45:52–59.
Metzner KJ, Giulieri SG, Knoepfel SA, et al. Minority quasispecies
of drug-resistant HIV-1 that lead to early therapy failure
in treatment-naive and -adherent patients. Clin Infect Dis,
2009, 48:239–247.
Miller DS, Bauer B, Hartz AM. Modulation of P-glycoprotein
at the blood-brain barrier: Opportunities to improve central
nervous system pharmacotherapy. Pharmacol Rev, 2008,
60:196–209.
Moise-Broder PA, Sakoulas G, Eliopoulos GM, et al. Accessory
gene regulator group II polymorphism in methicillin-resistant
Staphylococcus aureus is predictive of failure of vancomycin
therapy. Clin Infect Dis, 2004, 38:1700–1705.
Mondon P, Petter R, Amalfitano G, et al. Heteroresistance to
fluconazole and voriconazole in Cryptococcus neoformans.
Antimicrob Agents Chemother, 1999, 43:
1856–1861.
Nakajima Y. Mechanisms of bacterial resistance to macrolide
antibiotics. J Infect Chemother, 1999, 5:61–74.
Neumann AU, Lam NP, Dahari H, et al. Hepatitis C viral dynamics
in vivo and the antiviral efficacy of interferon-alpha therapy.
Science, 1998, 282:103–107.
Nijhuis M, van Maarseveen NM, Boucher CA. Antiviral resistance
and impact on viral replication capacity: Evolution of
viruses under antiviral pressure occurs in three phases. Handb
Exp Pharmacol, 2009, 189:299–320.
Ouellette M. Biochemical and molecular mechanisms of drug
resistance in parasites. Trop Med Int Health, 2001, 6:
874–882.
Panlilio AL, Cardo DM, Grohskopf LA, et al. Updated U.S.
Public Health Service guidelines for the management of occupational
exposures to HIV and recommendations for postexposure
prophylaxis. MMWR Recomm Rep, 2005, 54:1–17.
Pappas PG, Kauffman CA, Andes D, et al. Clinical practice
guidelines for the management of candidiasis: 2009 update by
the Infectious Diseases Society of America. Clin Infect Dis,
2009, 48:503–535.
Pasteur L. Mémoire sur les corpuscles organisés qui existent
dans l’atmosphère. Examen de la doctrine des générations
spontanées. Annales des sciences naturelles, 1861, 16:
5–98.
Petropoulos CJ, Parkin NT, Limoli KL, et al. A novel phenotypic
drug susceptibility assay for human immunodeficiency
virus type 1. Antimicrob Agents Chemother, 2000, 44:
920–928.
Preston SL, Drusano GL, Berman AL, et al. Pharmacodynamics
of levofloxacin: A new paradigm for early clinical trials.
JAMA, 1998, 279:125–129.
SECTION VII
CHEMOTHERAPY OF MICROBIAL DISEASES
Pukrittayakamee S, Wanwimolruk S, Stepniewska K, et al.
Quinine pharmacokinetic-pharmacodynamic relationships in
uncomplicated falciparum malaria. Antimicrob Agents
Chemother, 2003, 47:3458–3463.
Quagliarello VJ, Scheld WM. Treatment of bacterial meningitis.
N Engl J Med, 1997, 336:708–716.
Rad ME, Bifani P, Martin C, et al. Mutations in putative mutator
genes of Mycobacterium tuberculosis strains of the W-Beijing
family. Emerg Infect Dis, 2003, 9:838–845.
Rinder H. Hetero-resistance: An under-recognised confounder
in diagnosis and therapy? J Med Microbiol, 2001, 50:
1018–1020.
Sheiner LB, Rosenberg B, Marathe VV. Estimation of population
characteristics of pharmacokinetic parameters from routine
clinical data. J Pharmacokinet Biopharm, 1977,
5:445–479.
Singh N. Preemptive therapy versus universal prophylaxis with
ganciclovir for cytomegalovirus in solid organ transplant recipients.
Clin Infect Dis, 2001, 32:742–751.
Singh N, Wannstedt C, Keyes L, et al. Valganciclovir as preemptive
therapy for cytomegalovirus in cytomegalovirus-seronegative
liver transplant recipients of cytomegalovirus-seropositive donor
allografts. Liver Transpl, 2008, 14:240–244.
Spratt BG. Resistance to antibiotics mediated by target alterations.
Science, 1994, 264:388–393.
Stepniewska K, Chotivanich K, Brockman A, et al.
Overestimating resistance in field testing of malaria parasites:
Simple methods for estimating high EC50 values using a
Bayesian approach. Malar J, 2007, 6:4.
Talal AH, Ribeiro RM, Powers KA, et al. Pharmacodynamics of
PEG-IFN alpha differentiate HIV/HCV coinfected sustained
virological responders from nonresponders. Hepatology, 2006,
43:943–953.
Tam VH, Louie A, Deziel MR, et al. The relationship between
quinolone exposures and resistance amplification is characterized
by an inverted U: A new paradigm for optimizing pharmacodynamics
to counterselect resistance. Antimicrob Agents
Chemother, 2007, 51:744–747.
Tarning J, Ashley EA, Lindegardh N, et al. Population pharmacokinetics
of piperaquine after two different treatment regimens
with dihydroartemisinin-piperaquine in patients with
Plasmodium falciparum malaria in Thailand. Antimicrob
Agents Chemother, 2008, 52:1052–1061.
Vogelman B, Gudmundsson S, Leggett J, et al. Correlation of
antimicrobial pharmacokinetic parameters with therapeutic
efficacy in an animal model. J Infect Dis, 1988, 158:
831–847.
Wagenlehner FM, Kinzig-Schippers M, Sorgel F, et al.
Concentrations in plasma, urinary excretion and bactericidal
activity of levofloxacin (500 mg) versus ciprofloxacin (500 mg)
in healthy volunteers receiving a single oral dose. Int J
Antimicrob Agents, 2006, 28:551–519.
Wehrli W, Knusel F, Schmid K, Staehelin M. Interaction of
rifamycin with bacterial RNA polymerase. Proc Natl Acad Sci
U S A, 1968, 61:667–673.
Wilkins JJ, Savic RM, Karlsson MO, et al. Population pharmacokinetics
of rifampin in pulmonary tuberculosis patients,
including a semimechanistic model to describe variable
absorption. Antimicrob Agents Chemother, 2008, 52:
2138–2148.